Prescription drugs
The Clinician-Patient Working Alliance: Is It a Significant Predictor of Psychiatric Medication Adherence in a Sample of Recently Released Parolees
Concomitant Use of Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder and Benzodiazepines: Using the Prescription Behavior Surveillance System
Psychosocial Correlates of Clinicians Prescription Drug Monitoring Program Utilization
Law Enforcement Officers' Perceptions of Florida's Prescription Drug Monitoring Program
Office of Justice Programs (OJP) / Centers for Disease Control and Prevention (CDC) Federal Medicolegal Death Investigation Interagency Working Group (MDI-IWG) Resource Page
The Department of Justice’s (DOJ) Office of Justice Programs (OJP) and the U.S. Health and Human Services’ (HHS) Center for Disease Control and Prevention (CDC) established this Federal Medicolegal Death Investigation (MDI) Interagency Working Group (MDI-IWG) to coordinate Federal initiatives to strengthen MDI systems and support death investigation services practiced by medical examiner and coroner offices (MECs) across the United States. The MDI-IWG commenced in...
Fatal Poisonings Involving Propoxyphene Before and After Voluntary Withdrawal From the United States Market: An Analysis From the State of Florida
Law Enforcement Resources
OJP, along with DOJ partners, are committed to supporting and protecting America's law enforcement. Featured resources include officer safety & wellness, DOJ resources, VALOR, tribal law enforcement, and helping law enforcement combat opioids.